The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
BordenE.C., AmatoD.A., RosenbaumC.Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol.1987; 5(6): 840–850.
2.
ZalupskiM., MetchB., BalcerzakW.S.Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group Study. J Natl Cancer Inst.1991; 83(13): 926–932.
3.
AntmanK., CrowleyJ., BalcerzakS.P.An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol.1993; 11(7): 1276–1285.
4.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Soft Tissue Sarcoma. V.2.2014. http://www.nccn.org. Accessed April 1, 2014.
5.
TrisselL.A.Handbook on Injectable Drugs.17th ed.Bethesda, MD: American Society of Health-System Phamacists; 2013: 416.
6.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
7.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines – Antiemesis. V.2.2014. http://www.nccn.org. Accessed April 01, 2014.
Multinational Association for Supportive Care in Cancer. Antiemetic guidelines.2013. http://www.mascc.org. Accessed April 1, 2014.
10.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
11.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
12.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
13.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
14.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
15.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
SmithT.J., KhatcheressianJ., LymanG.H.2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
20.
NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. V.2.2014 http://www.nccn.org. Accessed November 18, 2014.
21.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
22.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
23.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
24.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
AronoffG.R., BennettW.M., BernsJ.S., BrierM.E., KasbekarN., MuellerB.A., PaskoD.A., SmoyerWE.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
